Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 425

1.

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance.

Cascetta P, Cavaliere A, Piro G, Torroni L, Santoro R, Tortora G, Melisi D, Carbone C.

Int J Mol Sci. 2018 Oct 25;19(11). pii: E3331. doi: 10.3390/ijms19113331. Review.

2.

Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma.

Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R.

Urol Oncol. 2018 Oct 6. pii: S1078-1439(18)30338-7. doi: 10.1016/j.urolonc.2018.08.018. [Epub ahead of print]

PMID:
30301699
3.

Hybrid Soft-Rigid Actuators for Minimally Invasive Surgery.

Paternò L, Tortora G, Menciassi A.

Soft Robot. 2018 Oct 3. doi: 10.1089/soro.2017.0140. [Epub ahead of print]

PMID:
30281418
4.

Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?

Pilotto S, Carbognin L, Rossi A, Tortora G, Bria E.

Semin Oncol. 2018 Sep 22. pii: S0093-7754(18)30169-6. doi: 10.1053/j.seminoncol.2018.08.002. [Epub ahead of print]

PMID:
30262399
5.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

PMID:
30193240
6.

Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer.

Iacovelli R, Ciccarese C, Mosillo C, Bimbatti D, Fantinel E, Stefani L, Simbolo M, Romano M, Mazzarotto R, Brunelli M, Bria E, Scarpa A, Lawlor RT, Artibani W, Tortora G.

Target Oncol. 2018 Oct;13(5):649-655. doi: 10.1007/s11523-018-0588-8.

PMID:
30167971
7.

Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis.

Iacovelli R, Ciccarese C, Bria E, Bimbatti D, Fantinel E, Mosillo C, Bisogno I, Brunelli M, Tortora G, Porta C.

Cancer Treat Rev. 2018 Nov;70:112-117. doi: 10.1016/j.ctrv.2018.08.007. Epub 2018 Aug 20. Review.

PMID:
30145397
8.

De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?

Iacovelli R, Ciccarese C, Mosillo C, Tortora G.

Clin Genitourin Cancer. 2018 Jul 20. pii: S1558-7673(18)30470-1. doi: 10.1016/j.clgc.2018.07.014. [Epub ahead of print]

PMID:
30139716
9.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

PMID:
30137196
10.

De novo metastatic castration sensitive prostate cancer: State of art and future perspectives.

Mosillo C, Iacovelli R, Ciccarese C, Fantinel E, Bimbatti D, Brunelli M, Bisogno I, Kinspergher S, Buttigliero C, Tucci M, Caffo O, Tortora G.

Cancer Treat Rev. 2018 Nov;70:67-74. doi: 10.1016/j.ctrv.2018.08.005. Epub 2018 Aug 11. Review.

PMID:
30121492
11.

Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer.

Trestini I, Carbognin L, Monteverdi S, Zanelli S, De Toma A, Bonaiuto C, Nortilli R, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E.

Crit Rev Oncol Hematol. 2018 Sep;129:54-66. doi: 10.1016/j.critrevonc.2018.06.011. Epub 2018 Jun 21. Review.

PMID:
30097238
12.

Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.

di Noia V, D'Argento E, Pilotto S, Grizzi G, Caccese M, Iacovelli R, Tortora G, Bria E.

Expert Opin Biol Ther. 2018 Sep;18(9):937-945. doi: 10.1080/14712598.2018.1508445. Epub 2018 Aug 9.

PMID:
30075697
13.

Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.

Ciccarese C, Iacovelli R, Mosillo C, Tortora G.

Clin Genitourin Cancer. 2018 Oct;16(5):e1069-e1071. doi: 10.1016/j.clgc.2018.06.005. Epub 2018 Jun 21. No abstract available.

PMID:
30005936
14.

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer.

Salvatore L, Lombardo F, Tortora G.

JAMA Oncol. 2018 Sep 1;4(9):1297-1298. doi: 10.1001/jamaoncol.2018.1692. No abstract available.

PMID:
30003239
15.

Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.

Gkountakos A, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M, Tortora G, Scarpa A, Bria E, Corbo V.

Carcinogenesis. 2018 Jun 28. doi: 10.1093/carcin/bgy086. [Epub ahead of print]

PMID:
29955840
16.

Do immune checkpoint inhibitors need new studies methodology?

Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E.

J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131. Review.

17.

Investigation of the Persistence of Penicillin G and Dihydrostreptomycin Residues in Milk of Lactating Buffaloes ( Bubalus bubalis) Using Ultra-High-Performance Liquid Chromatography and Tandem Mass Spectrometry.

Chirollo C, Vassallo A, Dal Piaz F, Lamagna B, Tortora G, Neglia G, De Tommasi N, Severino L.

J Agric Food Chem. 2018 Jun 27;66(25):6388-6393. doi: 10.1021/acs.jafc.8b00229. Epub 2018 Jun 13.

PMID:
29862808
18.

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C.

Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.

PMID:
29846246
19.

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C.

Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7.

PMID:
29803346
20.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.

PMID:
29753637
21.

Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research.

Mosillo C, Ciccarese C, Bimbatti D, Fantinel E, Volta AD, Bisogno I, Zampiva I, Santoni M, Massari F, Brunelli M, Montironi R, Tortora G, Iacovelli R.

Cancer Treat Rev. 2018 Jun;67:29-33. doi: 10.1016/j.ctrv.2018.02.009. Epub 2018 May 2. Review.

PMID:
29753244
22.

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.

Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, Mafficini A, Rusev B, Corbo V, Capelli P, Bria E, Pedron S, Turri G, Lawlor RT, Tortora G, Bassi C, Guglielmi A, Scarpa A.

Sci Rep. 2018 May 8;8(1):7119. doi: 10.1038/s41598-018-25669-1.

23.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.

Lazzaro C, Barone C, Caprioni F, Cascinu S, Falcone A, Maiello E, Milella M, Pinto C, Reni M, Tortora G.

Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):435-446. doi: 10.1080/14737167.2018.1464394. Epub 2018 Apr 20.

PMID:
29641931
24.

MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.

Santoro R, Zanotto M, Carbone C, Piro G, Tortora G, Melisi D.

Anticancer Res. 2018 Apr;38(4):1937-1946.

PMID:
29599309
25.

Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.

Trestini I, Carbognin L, Sperduti I, Bonaiuto C, Auriemma A, Melisi D, Salvatore L, Bria E, Tortora G.

Eur J Clin Nutr. 2018 May;72(5):772-779. doi: 10.1038/s41430-018-0155-5. Epub 2018 Mar 26.

PMID:
29581564
26.

Influence of time orientation on food choice: Case study with cookie labels.

Tórtora G, Ares G.

Food Res Int. 2018 Apr;106:706-711. doi: 10.1016/j.foodres.2018.01.045. Epub 2018 Jan 31.

PMID:
29579977
27.

Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.

Piro G, Carbone C, Santoro R, Tortora G, Melisi D.

Expert Rev Mol Diagn. 2018 Apr;18(4):357-370. doi: 10.1080/14737159.2018.1454312. Epub 2018 Mar 21.

PMID:
29544370
28.

The obesity paradox in cancer: clinical insights and perspectives.

Trestini I, Carbognin L, Bonaiuto C, Tortora G, Bria E.

Eat Weight Disord. 2018 Apr;23(2):185-193. doi: 10.1007/s40519-018-0489-y. Epub 2018 Feb 28. Review.

PMID:
29492860
29.

A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3.

Schepers D, Tortora G, Morisaki H, MacCarrick G, Lindsay M, Liang D, Mehta SG, Hague J, Verhagen J, van de Laar I, Wessels M, Detisch Y, van Haelst M, Baas A, Lichtenbelt K, Braun K, van der Linde D, Roos-Hesselink J, McGillivray G, Meester J, Maystadt I, Coucke P, El-Khoury E, Parkash S, Diness B, Risom L, Scurr I, Hilhorst-Hofstee Y, Morisaki T, Richer J, Désir J, Kempers M, Rideout AL, Horne G, Bennett C, Rahikkala E, Vandeweyer G, Alaerts M, Verstraeten A, Dietz H, Van Laer L, Loeys B.

Hum Mutat. 2018 May;39(5):621-634. doi: 10.1002/humu.23407. Epub 2018 Mar 6.

30.

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.

Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G, Melisi D.

Int J Mol Sci. 2018 Feb 1;19(2). pii: E431. doi: 10.3390/ijms19020431. Review.

31.

Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?

De Robertis R, Maris B, Cardobi N, Tinazzi Martini P, Gobbo S, Capelli P, Ortolani S, Cingarlini S, Paiella S, Landoni L, Butturini G, Regi P, Scarpa A, Tortora G, D'Onofrio M.

Eur Radiol. 2018 Jun;28(6):2582-2591. doi: 10.1007/s00330-017-5236-7. Epub 2018 Jan 19.

PMID:
29352378
32.

The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.

Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G.

Clin Genitourin Cancer. 2018 Jun;16(3):e645-e653. doi: 10.1016/j.clgc.2017.12.007. Epub 2017 Dec 27.

PMID:
29339044
33.

Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.

Pilotto S, Sperduti I, Leuzzi G, Chiappetta M, Mucilli F, Ratto GB, Lococo F, Filosso PL, Spaggiari L, Novello S, Milella M, Santo A, Scarpa A, Infante M, Tortora G, Facciolo F, Bria E.

J Thorac Oncol. 2018 Apr;13(4):568-575. doi: 10.1016/j.jtho.2017.12.003. Epub 2017 Dec 18.

PMID:
29269009
34.

The development of PARP as a successful target for cancer therapy.

Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.

Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26. Review.

PMID:
29260919
35.

Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.

Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, De Franceschi L, Scarpa A, Tortora G, Melisi D.

Int J Obes (Lond). 2018 Mar;42(3):334-343. doi: 10.1038/ijo.2017.285. Epub 2017 Nov 20.

36.

First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.

Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P.

Oncologist. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13.

PMID:
29133514
37.

Search for genetic factors in bicuspid aortic valve disease: ACTA2 mutations do not play a major role.

Tortora G, Wischmeijer A, Berretta P, Alfonsi J, Di Marco L, Barbieri A, Marconi C, Isidori F, Rossi C, Leone O, Di Bartolomeo R, Seri M, Pacini D.

Interact Cardiovasc Thorac Surg. 2017 Nov 1;25(5):813-817. doi: 10.1093/icvts/ivx242.

PMID:
29049801
38.

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.

Grizzi G, Caccese M, Gkountakos A, Carbognin L, Tortora G, Bria E, Pilotto S.

Expert Rev Mol Diagn. 2017 Dec;17(12):1055-1069. doi: 10.1080/14737159.2017.1393333. Epub 2017 Oct 23. Review.

PMID:
29032709
39.

Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours.

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MCJ, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Hiriyur Nagaraj S, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Vittoria Davì M, Landoni L, Malpaga A, Miotto M, Whitehall VLJ, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LMS, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2017 Oct 26;550(7677):548. doi: 10.1038/nature24026. Epub 2017 Sep 27.

PMID:
28953865
40.

A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma.

Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, Casolino R, Santoro R, Mina MM, Zecchetto C, Merz V, Scarpa A, Bassi C, Tortora G, Melisi D.

Oncoimmunology. 2017 Apr 28;6(9):e1322242. doi: 10.1080/2162402X.2017.1322242. eCollection 2017.

41.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
42.

Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.

Pilotto S, Carbognin L, Karachaliou N, Ma PC, Rosell R, Tortora G, Bria E.

Cancer Treat Rev. 2017 Nov;60:1-11. doi: 10.1016/j.ctrv.2017.08.002. Epub 2017 Aug 20. Review.

PMID:
28843992
43.

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.

Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G.

Eur J Cancer. 2017 Sep;83:237-246. doi: 10.1016/j.ejca.2017.06.030. Epub 2017 Jul 27. Review.

PMID:
28756136
44.

The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome.

Massari F, Ciccarese C, Hes O, Michal M, Caliò A, Fiorentino M, Giunchi F, D'Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M.

Pathol Oncol Res. 2018 Jul;24(3):447-456. doi: 10.1007/s12253-017-0271-x. Epub 2017 Jul 10. Review.

PMID:
28695322
45.

Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay.

De Robertis R, Paiella S, Cardobi N, Landoni L, Tinazzi Martini P, Ortolani S, De Marchi G, Gobbo S, Giardino A, Butturini G, Tortora G, Bassi C, D'Onofrio M.

Abdom Radiol (NY). 2018 Mar;43(3):613-619. doi: 10.1007/s00261-017-1243-z. Review.

PMID:
28677005
46.

Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.

Carbognin L, Sperduti I, Fabi A, Dieci MV, Kadrija D, Griguolo G, Pilotto S, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Caliò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E.

Breast. 2017 Oct;35:21-26. doi: 10.1016/j.breast.2017.06.005. Epub 2017 Jun 17.

PMID:
28628772
47.

The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.

Ciccarese C, Iacovelli R, Bria E, Modena A, Massari F, Brunelli M, Fantinel E, Bimbatti D, Zamboni GA, Artibani W, Tortora G.

Immunotherapy. 2017 Jun;9(7):579-587. doi: 10.2217/imt-2017-0018.

PMID:
28595514
48.

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G.

Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

PMID:
28572027
49.

Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F.

Curr Drug Metab. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549. Review.

PMID:
28524006
50.

Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.

D'Onofrio M, Cingarlini S, Ortolani S, Crosara S, DE Robertis R, Vallerio P, Grego E, Ciaravino V, Ruzzenente A, Landoni L, Scarpa A, Bassi C, Tortora G.

Anticancer Res. 2017 Mar;37(3):1305-1311.

PMID:
28314296

Supplemental Content

Loading ...
Support Center